Sagimet Biosciences Inc. financial data

Symbol
SGMT on Nasdaq
Location
San Mateo, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 3% % -71%
Return On Equity -42% % -79%
Return On Assets -40% % -76%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 30,674,855 shares 44%
Entity Public Float $102,200,000 USD
Weighted Average Number of Shares Outstanding, Basic 32,464,893 shares 1%
Weighted Average Number of Shares Outstanding, Diluted 32,464,893 shares 1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $46,536,000 USD 56%
General and Administrative Expense $17,783,000 USD 12%
Operating Income (Loss) $64,319,000 USD -41%
Net Income (Loss) Attributable to Parent $57,671,000 USD -54%
Earnings Per Share, Basic -1 USD/shares -103%
Earnings Per Share, Diluted -1 USD/shares -103%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $32,496,000 USD -58%
Marketable Securities, Current $84,197,000 USD 12%
Cash, Cash Equivalents, and Short-term Investments $125,500,000 USD -26%
Other Assets, Current $253,000 USD 150%
Assets, Current $119,480,000 USD -24%
Operating Lease, Right-of-Use Asset $115,000 USD 0.88%
Other Assets, Noncurrent $62,000 USD
Assets $128,401,000 USD -27%
Accounts Payable, Current $4,243,000 USD 268%
Employee-related Liabilities, Current $1,292,000 USD 30%
Accrued Liabilities, Current $4,788,000 USD 70%
Liabilities, Current $9,146,000 USD
Liabilities $7,180,000 USD 59%
Accumulated Other Comprehensive Income (Loss), Net of Tax $117,000 USD -73%
Retained Earnings (Accumulated Deficit) $336,781,000 USD -21%
Stockholders' Equity Attributable to Parent $119,255,000 USD -30%
Liabilities and Equity $128,401,000 USD -27%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $14,536,000 USD -134%
Net Cash Provided by (Used in) Financing Activities $104,846,000 USD
Net Cash Provided by (Used in) Investing Activities $3,413,000 USD 14%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $32,496,000 USD -58%
Deferred Tax Assets, Valuation Allowance $66,391,000 USD 20%
Deferred Tax Assets, Gross $66,407,000 USD 20%
Operating Lease, Liability $78,000 USD 20%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $57,995,000 USD -56%
Lessee, Operating Lease, Liability, to be Paid $80,000 USD 21%
Operating Lease, Liability, Current $115,000 USD -0.86%
Lessee, Operating Lease, Liability, to be Paid, Year One $80,000 USD 21%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 29%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $2,000 USD 100%
Deferred Tax Assets, Operating Loss Carryforwards $35,045,000 USD 13%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $2,186,000 USD 23%
Additional Paid in Capital $455,916,000 USD 1.5%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $16,000 USD -63%
Share-based Payment Arrangement, Expense $6,292,000 USD 24%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%